- Information Center
- Investment News
According to Yonhap News,
(SEOUL=Yonhap News) The Korea Institute of Science and Technology Information (KISTI) said that it will sign a Cooperative Research & Development Agreement (CRADA) for technology commercialization with mProbe at its headquarters in Daejeon on January 22.
mProbe was founded in 2016 based on the metabolite and protein analytical technologies of Stanford university researchers.
The company has been recognized as an emerging company in the precision medicine industry, with its development of gestational hypertension diagnosis marker attracting about KRW 50 billion investment.
It has been expanding by acquiring a in-vitro diagnostics company of the U.S, and establishing offices in China, Hong Kong and Taiwan.
mProbe plans to establish a mProbe Korea (tentative name) as a Innopolis Research Institute Spin-Off Company within next month.
The mProbe Korea is expected to develop and commercialize solutions for preterm delivery prediction and type-2 diabetes .
KISTI said that this agreement has been realized upon the request from a Stanford University research team led by professor Bruce Ling and CEO Peter Chen of mProbe who were interested in high performance computing-based Omics analytics.
The president of KISTI said "it will be an integration of KISTI's big data-based expertise in the bio-medical sector, infrastructure of world-class supercomputer NURION, and technology of Stanford's researchers," adding that "we hope this agreement sets an example of contribution to a new industry".
Copyrights Yonhap News. All Rights Reserved.
Reprint or redistribution without permission is prohibited.
Source: Yonhap News (January 21, 2019)
** This article was translated from Korean.